NCT02206360Completed
Pancreatic Cancer Early Detection Program
Observational Study to Analyze the Outcomes of Subjects Who - Based Upon Their Sufficiently Elevated Risk for the Development of Pancreatic Adenocarcinoma- Elect to Undergo Early Detection Testing
Source: ClinicalTrials.gov · Last updated 25 Aug 2026
Brief summary (registry, in English)
Early detection testing is recommended for individuals at elevated risk for the development of Pancreatic Cancer. This Protocol will define sufficiently elevated risk as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk. Our inclusion criteria has a strong focus on the risk for pancreatic cancer imparted by the presence of hereditary cancer genes, as well as by family history. Enrolled subjects will undergo Endoscopic Ultrasound (EUS) alternating with Magnetic Resonance Imaging (MRI), every six to 12 months, for up to 5 years.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 181 (actual)
- First submitted
- 29 Jul 2014
- Start date
- Apr 2014
- Primary completion date
- Mar 2024
- Lead sponsor
- White Plains Hospital
- Diseases
- Melanoma, Pancreatic cancer
- NCT number
- NCT02206360
What you commit to
- Study type: Observational
- Participants enrolled: 181
- From Apr 2014 to the primary completion date, Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Status post partial or complete resection of the pancreas
- Clinical suspicion of pancreatic cancer, or any previous radiographic or histologic diagnosis of a pre-malignant finding, including IPMN (Intraductal papillary mucinous neoplasm) and PanIN (Pancreatic intraepithelial Neoplasm).
Other illness
- Any medical condition that contraindicates endoscopy or biopsy
- Any medical condition that contraindicates MRI
- History of pancreatic cancer, either endocrine or exocrine
- diagnosis of dementia
- Uncontrolled, current illness
Lab values
- Renal insufficiency with serum creatinine greater than 2.0 mg/dl
Who the study is looking for
- Known carrier of either the BRCA2 or CDKN2A mutation;
- Known carrier of any of the following mutations (BRCA1, MLH1, MSH2, PMS2, MSH6, EPCAM , P53, PALB2, APC, or ATM) PLUS first or second degree relative affected with pancreatic cancer;
- Individual with Peutz-Jeghers Syndrome;
- Familial Pancreatic Cancer, defined as at least two affected relatives with Pancreatic Cancer, who are first degree relatives with each other, and at least one of those affected must be first degree relative to the study subject;
- Both parents affected, any age:
- Any first degree relative diagnosed with pancreatic cancer under age 50;
- Chronic Pancreatitis Syndrome, defined by either PRSS1 or SPINK1 mutations AND appropriate clinical and family history
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| White Plains Hospital Coordinator of this site? Confirm its status | White Plains | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.